News & Updates
Filter by Specialty:
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
The use of vedolizumab in the treatment of older patients with inflammatory bowel disease (IBD) appears to not only pose a higher risk of treatment failure but also offer no significant safety advantage when compared with tumour necrosis factor (TNF) antagonists, according to a study.
Treatment failure risk in older IBD patients higher with vedolizumab vs TNF antagonists
25 Oct 2022
Baseline HRQOL predicts survival in after radical prostatectomy
Baseline health-related quality of life (HRQOL) among patients with localized high-risk prostate cancer prior to radical prostatectomy is an important and a strong predictor of survival, suggests a study.
Baseline HRQOL predicts survival in after radical prostatectomy
24 Oct 2022
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
Sequential intravesical valrubicin and docetaxel prove to be an effective salvage treatment for patients with recurrent nonmuscle-invasive bladder cancer (NMIBC), a study has shown.
Docetaxel, valrubicin do well as rescue treatment for recurrent NMIBC
24 Oct 2022
Poor sleep quality, depression predict sexual dysfunction in women
Sexual dysfunction in women is associated with several factors, including senility, dissatisfaction with sleep, not having a partner, complaints of depression, low education, insufficient income, and worse perception of global health, according to a Brazil study.
Poor sleep quality, depression predict sexual dysfunction in women
23 Oct 2022
Prophylactic anticoagulation in critical COVID-19: Is full-dose or standard-dose preferred?
A full-dose prophylactic anticoagulation strategy reduced the risk of thrombosis in critically ill patients with COVID-19 who required intensive care unit (ICU)-level care compared with a standard-dose strategy, according to results of the COVID-PACT trial.
